


PHARMACEUTICAL 2019

Assertio Therapeutics Inc Rank 217 of 363





PHARMACEUTICAL 2019

Assertio Therapeutics Inc Rank 217 of 363

The relative strengths and weaknesses of Assertio Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Assertio Therapeutics Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 157% points. The greatest weakness of Assertio Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 51%, being 14% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	208,107
Cost of Goods Sold	0
Intangible Assets	692,099
Liabilities, Current	246,036
Liabilities, Non-Current	19,350
Other Assets	19,596
Other Compr. Net Income	0
Other Expenses	210,832
Other Liabilities	447,145
Other Net Income	63,197
Other Revenues	311,770
Property and Equipment	13,064
Research and Development	8,042
Selling, General and Administrative Expense	119,218

Output Variable	Value in 1000 USD
Assets	932,866
Liabilities	712,531
Expenses	338,092
Revenues	311,770
Stockholders Equity	220,335
Net Income	36,875
Comprehensive Net Income	36,875
Economic Capital Ratio	51%

